US20100065989A1 - Resorbable hollow devices for implantation and delivery of therapeutic agents - Google Patents
Resorbable hollow devices for implantation and delivery of therapeutic agents Download PDFInfo
- Publication number
- US20100065989A1 US20100065989A1 US12/624,217 US62421709A US2010065989A1 US 20100065989 A1 US20100065989 A1 US 20100065989A1 US 62421709 A US62421709 A US 62421709A US 2010065989 A1 US2010065989 A1 US 2010065989A1
- Authority
- US
- United States
- Prior art keywords
- resorbable
- tube
- balloon
- heating
- cooling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title abstract description 65
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 62
- 238000012384 transportation and delivery Methods 0.000 title abstract description 29
- 238000002513 implantation Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 60
- 238000010438 heat treatment Methods 0.000 claims description 25
- 238000001816 cooling Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000003466 welding Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 18
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 239000002639 bone cement Substances 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 238000005538 encapsulation Methods 0.000 abstract description 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 35
- 210000000988 bone and bone Anatomy 0.000 description 18
- 238000010586 diagram Methods 0.000 description 11
- 239000004568 cement Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 8
- -1 polyoxaesters Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000012907 medicinal substance Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010015866 Extravasation Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920001299 polypropylene fumarate Polymers 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000002355 open surgical procedure Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001230 polyarylate Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010041541 Spinal compression fracture Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/70—Spinal positioners or stabilisers ; Bone stabilisers comprising fluid filler in an implant
- A61B17/7097—Stabilisers comprising fluid filler in an implant, e.g. balloon; devices for inserting or filling such implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/8802—Equipment for handling bone cement or other fluid fillers
- A61B17/8833—Osteosynthesis tools specially adapted for handling bone cement or fluid fillers; Means for supplying bone cement or fluid fillers to introducing tools, e.g. cartridge handling means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/885—Tools for expanding or compacting bones or discs or cavities therein
- A61B17/8852—Tools for expanding or compacting bones or discs or cavities therein capable of being assembled or enlarged, or changing shape, inside the bone or disc
- A61B17/8855—Tools for expanding or compacting bones or discs or cavities therein capable of being assembled or enlarged, or changing shape, inside the bone or disc inflatable, e.g. kyphoplasty balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable or resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/8802—Equipment for handling bone cement or other fluid fillers
- A61B17/8805—Equipment for handling bone cement or other fluid fillers for introducing fluid filler into bone or extracting it
- A61B2017/8813—Discharging means for excessively introduced fluid fillers, e.g. discharging excess cement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/8802—Equipment for handling bone cement or other fluid fillers
- A61B2017/883—Means for indicating hardening of bone cement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4601—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for introducing bone substitute, for implanting bone graft implants or for compacting them in the bone cavity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
- A61F2002/30064—Coating or prosthesis-covering structure made of biodegradable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
Definitions
- the present invention relates generally to implants and, more particularly, to biomedical balloons and applications employing such balloons.
- Balloon catheters have been employed in angioplasty applications for many years.
- a catheter having an inflatable balloon formed therein may be inserted into an artery percutaneously, and the balloon guided to a treatment area.
- the balloon may then be inflated in order to mitigate the effect of plaque deposits in, for example, a coronary artery.
- a balloon catheter is employed to implant a stent into an artery of a patient in order to decrease the likelihood of a recurrence of arterial blockage.
- Balloon catheters used in angioplasty are commonly removed from the patient after use as a result of, for example, typically being meant only to temporarily inflate the vessel or temporarily block the vessel for delivery of a stent or drugs. Additionally, removal of the balloon is typically necessary in order to attenuate complications that may arise pertaining, for example, to long-term effects which may stem from contact between a material of the balloon and the patient's tissue.
- Balloon devices have found utility in biomedical areas other than cardiovascular applications.
- balloons may be used in kyphoplasty applications wherein the effect of a vertebral fracture from osteoporosis is treated by inserting a balloon into a cavity formed in the fracture. Inflating the balloon may cause pieces of the fracture to return to a positions or orientations approximating those existing before for example a traumatic event that caused the fracture. Bone cement may then be inserted into the cavity in order to stabilize the bone fragments. In other vertebroplasty applications, bone cement may be inserted into, for example, cavities formed in weakened or fractured bones in order to provide enhanced strength and stability.
- cement extravasation can be a problem in these kyphoplasty and vertebroplasty situations.
- cement inserted into bone may extrude into surrounding tissues and nerves, causing pain and other complications.
- One way to prevent cement extravasation is to insert a balloon into the treatment cavity, fill the balloon with bone cement, and allow the cement to harden inside the balloon while the balloon remains in the body of the patient.
- Such a solution may not always be viable due for example to confounding factors such as situations wherein the presence of the balloon may prevent bonding between the bone cement and the bone tissue of interest. Consequently, gaps may form between an outer surface of the balloon and surrounding bone, introducing for example attendant risks of infection, bone loss, and pain.
- a medicinal substance can be administered to a patient systemically or locally.
- a systemically administered medicinal substance enters into the blood stream, travels throughout the body, and, preferentially, reaches the part of the patient's body in need of treatment at an effective dose before being degraded by metabolism and excreted.
- the systemic administration of medicinal substances can be achieved by oral application (e.g., syrups, tablets, capsules and the like), needle injection, transdermal delivery (e.g., a medicinal substance incorporated into a skin patch), and subdermal delivery (e.g., a medicinal substance formulation in a metabolizable matrix placed beneath the skin to release, for example, nicotine or birth control drugs).
- Systemically delivered medicinal substances can be inefficient when only a small amount of the administered dose reaches the site sought for therapeutic action.
- a medicinal substance can enter parts of the body where it can actually do harm or produce a noxious side effect.
- Medicinal substances can be delivered locally by injection (e.g., injection of anesthetic into a patient's gums) or topically (e.g., creams, ointments, and sprays).
- injection e.g., injection of anesthetic into a patient's gums
- topically e.g., creams, ointments, and sprays
- a therapeutic agent may be delivered locally by way of a timed-released or controlled delivery type device.
- timed-released devices are formed as a mixture or dispersion of the therapeutic agent in a degrading or non-degrading delivery material or vehicle.
- the therapeutic agent is destroyed, denatured, or looses its activity when combined with the delivery vehicle or material.
- controlled delivery devices rely on diffusion of the therapeutic agent from the delivery material or vehicle, but the therapeutic agent may be too large to diffuse through a delivery material matrix of the controlled delivery device at a reasonable rate.
- an open procedure may be required to insert a relatively large therapeutic time-release device to the desired anatomical location.
- many small devices may be inserted, such as microspheres. The microspheres, however, may be difficult to retrieve if there is a complication. Even when local delivery of medicinal substances to a target site is possible, an important consideration still remains of maximizing the therapeutic effectiveness of the local drug delivery by controlling the proper dose and duration of the local delivery of the medicinal substance.
- the present invention provides a resorbable (e.g., bioresorbable, degradable, biodegradable, absorbable, bioabsorbable, erodible, bioerodible) balloon that can encapsulate cement in vertebroplasty and kyphoplasty applications until the cement has an opportunity to harden, thereby preventing incursion of the cement into soft tissue and nerves in a vicinity of bone being treated.
- the invention herein disclosed includes a method of forming a resorbable balloon comprising, according to an illustrative implementation, extruding resorbable tubing and cutting the tubing to desired lengths, thereby forming a plurality of tubes.
- a region of a tube is heated, and the tubing that forms the tube can be pulled along an axis of the tube, thereby thinning a wall of the tube at the heated region. Heated air is forced through a lumen of the tube while heating the region of the tube so that the tubing expands and forms a balloon in the heated region.
- An end of the tube is sealed by a thermal method or by gluing a resorbable plug into the lumen, and excess tubing beyond the sealed point is removed.
- the resorbable balloon may be employed in a bone restoration procedure whereby a volume of bone is evacuated to form a cavity in the bone.
- a deflated resorbable balloon is inserted into the cavity, and the resorbable balloon is filled with bone cement, thereby inflating the balloon and filling the cavity.
- the resorbable balloon subsequently biodegrades to bring the bone cement into contact with bone within the cavity.
- the present invention further provides apparatus and methods that may avoid problems associated with prior art methods of delivering therapeutic agents.
- Delivery methods and devices of various embodiments of the present invention may provide delivery of therapeutic agents while avoiding or attenuating problems associated with one or more of: combinations of the therapeutic agent with a delivery material or vehicle, diffusion through a material of the delivery device, implantation of multitudes of small delivery devices, and open surgical procedures.
- the invention herein disclosed thus can employ resorbable hollow devices which can be introduced into a desired anatomical location with, in many instances, a minimum of trauma.
- an implementation of a method according to the present invention can comprise a first collapsible resorbable hollow device, such as a resorbable balloon.
- a surgical procedure which may be a laparoscopic procedure, may be performed to generate a cavity in a desired anatomical location of a body of a patient.
- the resorbable hollow device may be deflated, and subsequently inserted into the cavity.
- At least one therapeutic agent may be injected into the first collapsible resorbable hollow device.
- a second collapsible resorbable hollow device may be provided, and the second device may be inserted into the first collapsible resorbable hollow device.
- At least one therapeutic agent then may be injected into the second collapsible resorbable hollow device.
- a therapeutic agent may comprise one or more of a natural organic substance, a synthetic organic substance, an inorganic substance, and combinations thereof.
- An embodiment of the present invention may further comprise a collapsible resorbable balloon formed of resorbable material such as, for example, aliphatic polyesters, polycarbonates, polyoxaesters, polyorthoesters, polyanhydrides, polyphosphoesters, polyphosphazenes, polypropylene fumarates, polyamino acids, other polyamides, pseudopoly(amino acids), polyamidoesters, polyarylates, polyoxaesters containing amine groups, polyalkylene oxalate, polyhydroxybuyrate, polyhydroxyvalerate, resorbable polyurethanes, resorbable starches, resorbable silk, chitan or chitosan, and combinations (co- or multi-polymers or blends) of any of the above with or without, for example, nonresorbable polymers and/or natural substances.
- resorbable material such as, for example, aliphatic polyesters, polycarbonates, polyoxaesters
- FIG. 1 is a flow diagram describing an implementation of a method of manufacturing a resorbable balloon
- FIG. 3 is a simplified diagram illustrating a cavity in bone that may be filled with cement by employing a resorbable balloon according to the present invention
- FIG. 4 is a flow diagram describing an implementation of a method of delivering a therapy or therapeutic agent employing collapsible resorbable hollow devices
- FIG. 5 is a pictorial diagram illustrating three resorbable hollow devices according to an example of the present invention.
- FIG. 6 is a pictorial diagram illustrating the three resorbable hollow devices of FIG. 5 with openings sealed or closed in some way, if needed, and conduits removed;
- FIG. 7 is a graphical chart illustrating timed-release delivery of therapeutic agents.
- the present invention has applicability in the field of resorbable balloons or hollow devices in general.
- a biodegradable e.g., resorbable, bioresorbable, degradable, absorbable, bioabsorbable, erodible, or bioerodible
- biodegradable e.g., resorbable, bioresorbable, degradable, absorbable, bioabsorbable, erodible, or bioerodible
- FIG. 1 is a flow diagram describing an implementation of the inventive methods of manufacturing a resorbable (e.g., bioresorbable, degradable, biodegradable, absorbable, bioabsorbable, erodible, bioerodible) balloon.
- a resorbable e.g., bioresorbable, degradable, biodegradable, absorbable, bioabsorbable, erodible, bioerodible
- FIGS. 2 a - 2 g illustrate a representative sequence of performing steps of the methods.
- the illustrated embodiment of the described inventive methods comprises extruding resorbable tubing at step 10 .
- the tubing extruded may comprise, for example, polymeric tubing in a representative embodiment.
- FIG. 2 a illustrates an example of a mold 50 from which is extruded tubing 55 .
- the tubing 55 may have a circular cross-section with an outer diameter 60 ranging, for example, from about 0.7 mm to about 15 mm and an inner diameter 65 that may range, for example, from about 0.5 mm to about 9 mm. That is, the tubing may exhibit a wall thickness of, for example, about 0.1 mm to about 3 mm in common embodiments.
- the tubing 55 may be cut into portions at step 15 , wherein the portions may have various lengths according to varying intended applications. Tubes of resorbable material may thus be formed from the cutting performed at step 15 .
- a portion of tubing intended for use in angioplasty may range in length from, for example, about 50 mm to about 300 mm.
- a portion of tubing intended for use in vertebroplasty applications typically may be cut into lengths ranging in length from, for example, about 15 mm to about 100 mm.
- FIG. 2 b illustrates two such tubes 70 and 75 .
- a portion of the tubing, e.g. tube 70 may be heated in a selected region at step 20 .
- a center region of the tube may be selected and heated.
- FIG. 2 c illustrates a center region 85 of tube 70 being heated by an embodiment of an external heat source, which may comprise, for example, a mold formed, for example, of metal.
- the mold comprises a heated mold 90 .
- the heated mold 90 may comprise an internal chamber or cavity 91 having a shape and size equal or corresponding to, for example, one or more of a final balloon size and a final balloon shape.
- An exemplary embodiment of the heated mold 90 comprises electrical coils 92 through which may be passed a current 93 supplied from an electrical power source 94 .
- the heated mold 90 may in certain embodiments be configured to provide heat (and/or cooling), for example, in different amounts along one or more of: (a) at least one spatial dimension (e.g., along a longitudinal axis of the heated mold 90 ), and (b) a time dimension (e.g., at different points in time and/or for different durations).
- tubing when tubing is inserted into the heated mold 90 such that a longitudinal axis of the tubing is substantially aligned with a longitudinal axis of the heated mold 90 , and when as in the illustrated embodiment tubing near the center of the cavity 91 is substantially further from walls of the heated mold 90 than tubing at ends of the cavity 91 , greater amounts of heat energy may be provided near the center of the cavity 91 at certain points in time such as during the process of FIG. 2 e .
- the tubing can be inserted into the heated mold 90 prior to any pre-stretching of the tubing.
- Electrical coils in an illustrated embodiment of the heated mold 90 may be fabricated to have, for example, greater resistance in a center region of the heated mold 90 than at edges. Such an arrangement may provide greater I 2 R heating of metal near the center of the heated mold 90 , wherein I represents current and R represents resistance.
- the heated mold 90 comprises a block of metal housing electrical coils 92
- certain parts of the heated portions of electrical coils 92 may be formed to comprise greater resistances (or other heating structures) to thereby provide varying amounts of heat at the heated portions of the electrical coils 92 .
- the heated center region 85 which is indicated in FIG. 2 c with shading, is bounded by relatively unheated regions 80 and 81 of tubing on either side of the heated center region 85 .
- the material forming tube 70 may be pulled.
- the material forming the tube 70 is pulled while being heated.
- such pulling may accomplish one or more of strengthening and orienting a polymer or polymers of the tubing and causing the tubing wall to thin in the heated region.
- Exhaust air 111 may be directed out of the tube 70 via, for example, an end of the tube 70 that is opposite to an end through which the fluid is directed.
- the thickness of the wall 97 of the balloon 100 may in the illustrated embodiment be reduced to a thickness of, for example, about 0.005 mm to about 0.1 mm.
- FIG. 2 f illustrates an example of a balloon 100 formed according to the aforementioned steps after the heated mold 90 and a source of forced heated air 110 have been removed.
- the heated mold 90 may be partially or substantially completely (e.g., below a glass transition temperature) cooled before removal of the balloon 100 from the heated mold 90 .
- Fabrication of the balloon 100 can then be completed by, for example, at least partially modifying, e.g., sealing, an end of the tube near the balloon 100 at step 30 .
- a resorbable plug 115 is shown formed, e.g., integrally formed using heat, or affixed, e.g., adhered or glued, to an end of the balloon 100 , thereby providing, for example, a seal at an end of the tube that is disposed in close proximity to the balloon 100 .
- Excess tubing corresponding for example to a relatively unheated region 80 ( FIG. 2 f ), can be removed, e.g., cut off, beyond the sealed point as depicted in the embodiment of FIG.
- a diameter, e.g., a maximum diameter, of the access passageway 170 is less than a diameter, e.g., a maximum diameter, of the cavity 165 . In other embodiments, however, a diameter of the access passageway 170 may be about equal to or greater than a corresponding, e.g., measured in the same or similar direction, diameter of the cavity 165 .
- tubing comprising a resorbable balloon that is similar to the balloon 100 illustrated in FIG. 2 g can be formed as described herein.
- a property, e.g., dimension such as diameter, of the tubing is chosen such that the tubing and the balloon in its deflated state are capable of being inserted through access passageway 170 and into the cavity 165 .
- properties of the tubing and/or balloon may be selected such that the tubing and balloon may be folded to facilitate insertion through the access passageway 170 .
- the tubing and balloon are maneuvered through the access passageway 170 and into the cavity 165 using a catheter.
- a material such as bone cement may be inserted, e.g., injected, into a lumen of the tube.
- the material may be delivered directly into the balloon via the catheter, wherein, for example, the material does not contact internal surfaces of the tubing during transit to the balloon.
- Other implementations may comprise, for example, delivery of the material into the balloon via the tubing itself, wherein, for example, the material contacts the tubing during transit to the balloon.
- insertion of the material at least partially fills, e.g., inflates, the balloon.
- material comprising bone cement can be positioned within a resorbable, expandable balloon, combined, in some implementations, with one or more of an antiobiotic, analgesic, growth factor (such as Bone Morphogenetic Protein), or a combination thereof, to contact interior surfaces of a cavity formed within bone, thereby permitting one or more of reacting, hardening, and bonding to occur between the material and the bone upon resorption of the balloon. Consequently, risks of one or more of infection and pain can be attenuated or eliminated.
- an antiobiotic, analgesic, growth factor such as Bone Morphogenetic Protein
- the collapsible, resorbable hollow devices may be nested as illustrated, for example, in FIG. 5 .
- the collapsible, resorbable hollow devices may be designed to deliver or release at least one therapeutic agent.
- a conduit or tube may be attached, if needed (e.g., suitable or desired), to an opening of the device at step 120 of the implementation.
- the conduit may be formed as a continuous part of the hollow device.
- the conduit (see, e.g., FIG. 5 ) may facilitate loading of the hollow device with at least one therapeutic agent. Additionally, the conduit may aid in positional manipulation of the hollow device.
- a surgical procedure which may be a laparoscopic procedure, may be performed, if needed (e.g., suitable or desired), at step 130 to identify a cavity in an anatomical location.
- a cavity in a desired anatomical location may also be formed.
- a cavity may be formed in soft tissue using a tissue expander.
- a cavity may be formed in a collapsed vertebra of the spine of a patient, wherein therapy is to be performed.
- a cavity may be identified in the abdomen or other part of the body of a patient near an abscess requiring antibiotic therapy.
- the hollow device may, to the extent inflated, be at least partially deflated at step 140 , and the hollow device inserted into the cavity at step 150 .
- the attached conduit may facilitate insertion and positional manipulation of the hollow device.
- a therapeutic agent such as an antibiotic, may be injected into the hollow device at step 160 , thereby inflating the hollow device.
- the hollow device may be inflated before the therapeutic agent is injected.
- the inflating may be performed by altering an internal or external physical or chemical environment of the device when the device is in living tissue.
- the conduit may also be used to transfer the therapeutic agent into the hollow device.
- the opening may be closed at step 170 after which the conduit may then be removed, if needed (e.g., suitable or desired), from the hollow device at step 180 .
- the opening is closed after removal of the conduit.
- the opening is closed during removal of the conduit.
- the opening is not closed, as may occur when the device is used to transfer gelling or polymerizing substances as therapeutic agents.
- the therapeutic agent may be delivered in a time-released manner according to specific properties of the hollow device.
- the device may be fabricated with varying thicknesses or with relatively small perforations or holes, sizes of which may be adjusted to achieve a desired rate of delivery of the therapeutic agent.
- more than one collapsible, resorbable hollow device may be employed.
- a second collapsible device may be inserted inside a first collapsible hollow device, the first device then being injected with one or more or a combination of therapeutic agents.
- the second collapsible device then may be inflated, and yet another therapeutic agent or combination thereof may be injected into the second device.
- This process may be continued by nesting a plurality of collapsible, resorbable hollow devices in a manner that should be clear to one skilled in the art from the disclosure provided herein.
- openings of the hollow devices may be closed separately before, after, or during removal of conduits associated with each device. In some instances, the openings may be closed together.
- nested hollow devices may be made with differing materials or geometry (shapes). Alternatively, space, or lack of space, between the devices can be used to achieve desired patterns of release of therapeutic material.
- FIG. 5 is a pictorial diagram illustrating an embodiment comprising a plurality of nested hollow devices according to the present invention. Although only three such devices are illustrated in the figure, one skilled in the art will understand that more or fewer hollow devices may be employed so that a description of three devices is by way of example and not by way of limitation.
- a first collapsible, resorbable hollow device 200 is inflated and fully or partially filled with a first therapeutic agent 205 . That is, the first collapsible, resorbable hollow device 200 may, in some instances, be partially filled in order to leave room for insertion of subsequent hollow devices.
- the first therapeutic agent may comprise one or more or a combination of individual therapeutic agents.
- the first therapeutic agent 205 may be loaded into the first hollow device 200 through a first tube or first conduit 210 formed as part of the first hollow device. Loading of first therapeutic agent 205 is noted on the diagram by reference numeral 215 .
- a second collapsible, resorbable hollow device 220 may be inserted using second conduit 230 in deflated form, and the device 220 then may be partially or fully inflated.
- loading the second hollow device 220 with a second therapeutic material 225 through second conduit 230 as denoted by reference numeral 235 may serve to inflate the second hollow device 220 , thereby displacing or redistributing a portion of the first therapeutic agent 205 already loaded.
- a third collapsible, resorbable hollow device 240 may likewise be inserted into the second device 220 and loaded using third conduit 250 as indicated by reference numeral 255 .
- respective first, second, and third conduits 210 , 230 , and 250 may be removed using any of several methods well-known in the art, leaving, for example, seal 260 in place as illustrated in FIG. 6 .
- the collapsible, resorbable hollow devices 200 , 220 , and 240 illustrated in FIGS. 5 and 6 may be formed of various materials.
- a representative hollow device can be made with a resorbable synthetic polymer including by way of example, and not by way of limitation, one or more of aliphatic polyesters (e.g., polyL-lactide, polyD-lactide, polyglycolide, poly epsilon-caprolactone, and the like), polycarbonates (e.g., polytrimethylene carbonate, tyrosine derived polycarbonates, and polyiminocarbonates), polyoxaesters (e.g., polyp-dioxanone), polyorthoesters, polyanhydrides, polyphosphoesters, polyphosphazenes, polypropylene fumarates, polyamides (e.g., polyaminoacids), pseudopoly(amino acids), polyamidoesters, polyarylates, poly
- hollow devices may be made to resorb (e.g., bioresorb, degrade, biodegrade, absorb, bioabsorb, erode, or bioerode) over time periods ranging from a few days to a number of years according to a desired release rate of a therapeutic agent.
- resorb e.g., bioresorb, degrade, biodegrade, absorb, bioabsorb, erode, or bioerode
- Therapeutic agents may have the consistency of, for example, one or more of a liquid, gel, powder, small granules, spheres or chips, a polymerizable substance, and combinations thereof, and likewise, may be chosen from a variety of possibilities.
- a natural organic substance can be or include one or more of living biological agents (e.g., cells), proteins (e.g., growth factors such as Bone Morphogenetic Protein, and the like), other natural polymers (e.g., collagen, gelatin, fibrin, hyaluronic acid, polysaccharides, elastin, cellulose, polynucleotides), other biological materials, and the like. Combinations of these and similar materials also may be used.
- FIG. 7 is a chart illustrating in graphical form an example of how release of a therapeutic agent may be controlled through use of resorbable hollow devices in a repeat action dosage form.
- the chart illustrates a variation of local concentration or amount of a therapeutic agent on a vertical axis 300 during a time period drawn on a horizontal axis 305 .
- the amount of therapeutic agent to be released normally is to be kept between a minimum therapeutic level 310 and a maximum therapeutic level 315 .
- the maximum therapeutic level 315 may correspond as well to a toxicity level.
- the chart of FIG. 7 is keyed to the first, second, and third resorbable hollow devices 200 , 220 , and 240 depicted in FIGS. 5 and 6 .
- first hollow device 200 becomes resorbed (i.e. degrades) at a first time 320 releasing a first wave 325 of the therapeutic agent.
- first wave 325 decreases.
- second hollow device 220 degrades releasing a second wave 335 of the therapeutic agent.
- third hollow device 240 degrades at a third time 340 releasing a third wave 345 of the therapeutic agent.
- the actual elapsed time between degradation of the first, second, and third hollow devices 200 , 220 , and 240 may be controlled, as noted above, by choosing materials from which the devices are fabricated, and/or constructions (e.g., designing the devices with small holes or perforations), or the like.
- the time intervals between times 320 , 330 , and 340 may be the same or different.
- First, second, and third therapeutic agents 205 , 225 , and 245 ( FIGS. 5 and 6 ), likewise, may be the same or different in different embodiments of the present invention.
- first, second, and third therapeutic agents 205 , 225 , and 245 are the same agent, and the different degradation rates of the hollow devices 200 , 220 , and 240 serve to release the agent over a relatively long period of time, and/or possibly in short bursts, but, for example, above the therapeutic minimum level 310 and below the maximum therapeutic level or below the toxicity level 315 .
- a hollow device such as second hollow device 220
- the methods of the present invention can facilitate formation of resorbable balloons and control of time-release therapeutic agents using collapsible, resorbable hollow devices or balloons.
- the above-described embodiments have been provided by way of example, and the present invention is not limited to the described examples. Multiple variations and modifications to the disclosed embodiments will occur, to the extent not mutually exclusive, to those skilled in the art upon consideration of the foregoing description.
- the resorbable balloon may be used for other implanting applications such as a bariatric balloon, breast augmentation balloon, etc.
- modifications to the above-described manufacturing techniques may include, for example, a continuous extrusion and balloon forming method, and alternative implementations of such techniques may include, for example, extrusion of tubing with one closed end resembling the shape of, for example, a blow molding parison.
- Other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the disclosed embodiments, but is to be defined by reference to the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing & Machinery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 11/357,837, filed Feb. 16, 2006 and entitled RESORBABLE HOLLOW DEVICES FOR IMPLANTATION AND DELIVERY OF THERAPEUTIC AGENTS. U.S. application Ser. No. 11/357,837 claims the benefit of U.S. Provisional Application No. 60/653,778, filed Feb. 16, 2005 and entitled RESORBABLE BALLOON FOR BIOMEDICAL IMPLANTATION, and U.S. Provisional Application No. 60/672,839, filed Apr. 18, 2005 and entitled RESORBABLE HOLLOW DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS, the entire contents of both which are hereby incorporated by reference. This application also relates to U.S. application Ser. No. 10/129,214 (Docket MA9263P), filed Oct. 21, 2002 and entitled TIME-RELEASED SUBSTANCE DELIVERY DEVICE, the entire contents of which are hereby incorporated by reference.
- 1. Field of the Invention
- The present invention relates generally to implants and, more particularly, to biomedical balloons and applications employing such balloons.
- 2. Description of Related Art
- Balloon catheters have been employed in angioplasty applications for many years. A catheter having an inflatable balloon formed therein may be inserted into an artery percutaneously, and the balloon guided to a treatment area. The balloon may then be inflated in order to mitigate the effect of plaque deposits in, for example, a coronary artery. In some cases a balloon catheter is employed to implant a stent into an artery of a patient in order to decrease the likelihood of a recurrence of arterial blockage. Balloon catheters used in angioplasty are commonly removed from the patient after use as a result of, for example, typically being meant only to temporarily inflate the vessel or temporarily block the vessel for delivery of a stent or drugs. Additionally, removal of the balloon is typically necessary in order to attenuate complications that may arise pertaining, for example, to long-term effects which may stem from contact between a material of the balloon and the patient's tissue.
- Balloon devices have found utility in biomedical areas other than cardiovascular applications. For example, balloons may be used in kyphoplasty applications wherein the effect of a vertebral fracture from osteoporosis is treated by inserting a balloon into a cavity formed in the fracture. Inflating the balloon may cause pieces of the fracture to return to a positions or orientations approximating those existing before for example a traumatic event that caused the fracture. Bone cement may then be inserted into the cavity in order to stabilize the bone fragments. In other vertebroplasty applications, bone cement may be inserted into, for example, cavities formed in weakened or fractured bones in order to provide enhanced strength and stability.
- Unfortunately, cement extravasation can be a problem in these kyphoplasty and vertebroplasty situations. For instance, cement inserted into bone may extrude into surrounding tissues and nerves, causing pain and other complications. One way to prevent cement extravasation is to insert a balloon into the treatment cavity, fill the balloon with bone cement, and allow the cement to harden inside the balloon while the balloon remains in the body of the patient. Such a solution may not always be viable due for example to confounding factors such as situations wherein the presence of the balloon may prevent bonding between the bone cement and the bone tissue of interest. Consequently, gaps may form between an outer surface of the balloon and surrounding bone, introducing for example attendant risks of infection, bone loss, and pain.
- A need thus exists in the prior art for a method of preventing cement extravasation in vertebroplasty and kyphoplasty applications. A further need exists for enabling bonding between bone cement and bone tissue following vertebroplasty and kyphoplasty treatments.
- A medicinal substance can be administered to a patient systemically or locally. A systemically administered medicinal substance enters into the blood stream, travels throughout the body, and, preferentially, reaches the part of the patient's body in need of treatment at an effective dose before being degraded by metabolism and excreted. The systemic administration of medicinal substances can be achieved by oral application (e.g., syrups, tablets, capsules and the like), needle injection, transdermal delivery (e.g., a medicinal substance incorporated into a skin patch), and subdermal delivery (e.g., a medicinal substance formulation in a metabolizable matrix placed beneath the skin to release, for example, nicotine or birth control drugs). Systemically delivered medicinal substances can be inefficient when only a small amount of the administered dose reaches the site sought for therapeutic action. Moreover, with systemic delivery a medicinal substance can enter parts of the body where it can actually do harm or produce a noxious side effect.
- Medicinal substances can be delivered locally by injection (e.g., injection of anesthetic into a patient's gums) or topically (e.g., creams, ointments, and sprays). Although the local delivery of medicinal substances can in some instances overcome problems of dilution and migration associated with systemic administration, multiple injections may be required to achieve or sustain a therapeutically effective dose over time. To avoid a need for multiple injections, a therapeutic agent may be delivered locally by way of a timed-released or controlled delivery type device. In many cases, timed-released devices are formed as a mixture or dispersion of the therapeutic agent in a degrading or non-degrading delivery material or vehicle. In some cases the therapeutic agent is destroyed, denatured, or looses its activity when combined with the delivery vehicle or material. In other cases, controlled delivery devices rely on diffusion of the therapeutic agent from the delivery material or vehicle, but the therapeutic agent may be too large to diffuse through a delivery material matrix of the controlled delivery device at a reasonable rate. In cases where the volume of the therapeutic time-released agent is large, an open procedure may be required to insert a relatively large therapeutic time-release device to the desired anatomical location. To avoid an open procedure for the delivery of a large volume of therapeutic agent, many small devices may be inserted, such as microspheres. The microspheres, however, may be difficult to retrieve if there is a complication. Even when local delivery of medicinal substances to a target site is possible, an important consideration still remains of maximizing the therapeutic effectiveness of the local drug delivery by controlling the proper dose and duration of the local delivery of the medicinal substance.
- A need thus exists in the prior art for a delivery method or apparatus that can avoid undesirable activity losses of a therapeutic agent that may be associated with techniques that combine the therapeutic agent with a delivery material or vehicle. A further need exists for a method or apparatus that can avoid a requirement of diffusion of a therapeutic agent through a material of a delivery device. A still further need exists for methods or apparatus that may not require implantation of multitudes of small delivery devices and/or associated problems that may be presented of having to retrieve those small devices from an anatomical location upon the occurrence of complications, as well as methods or apparatus that may not require open surgical procedures for delivering large amounts of therapeutic agents.
- The present invention provides a resorbable (e.g., bioresorbable, degradable, biodegradable, absorbable, bioabsorbable, erodible, bioerodible) balloon that can encapsulate cement in vertebroplasty and kyphoplasty applications until the cement has an opportunity to harden, thereby preventing incursion of the cement into soft tissue and nerves in a vicinity of bone being treated. The invention herein disclosed includes a method of forming a resorbable balloon comprising, according to an illustrative implementation, extruding resorbable tubing and cutting the tubing to desired lengths, thereby forming a plurality of tubes. A region of a tube is heated, and the tubing that forms the tube can be pulled along an axis of the tube, thereby thinning a wall of the tube at the heated region. Heated air is forced through a lumen of the tube while heating the region of the tube so that the tubing expands and forms a balloon in the heated region. An end of the tube is sealed by a thermal method or by gluing a resorbable plug into the lumen, and excess tubing beyond the sealed point is removed. According to an illustrative example, the resorbable balloon may be employed in a bone restoration procedure whereby a volume of bone is evacuated to form a cavity in the bone. A deflated resorbable balloon is inserted into the cavity, and the resorbable balloon is filled with bone cement, thereby inflating the balloon and filling the cavity. The resorbable balloon subsequently biodegrades to bring the bone cement into contact with bone within the cavity.
- The present invention further provides apparatus and methods that may avoid problems associated with prior art methods of delivering therapeutic agents. Delivery methods and devices of various embodiments of the present invention may provide delivery of therapeutic agents while avoiding or attenuating problems associated with one or more of: combinations of the therapeutic agent with a delivery material or vehicle, diffusion through a material of the delivery device, implantation of multitudes of small delivery devices, and open surgical procedures. The invention herein disclosed thus can employ resorbable hollow devices which can be introduced into a desired anatomical location with, in many instances, a minimum of trauma. As an example, an implementation of a method according to the present invention can comprise a first collapsible resorbable hollow device, such as a resorbable balloon. A surgical procedure, which may be a laparoscopic procedure, may be performed to generate a cavity in a desired anatomical location of a body of a patient. The resorbable hollow device may be deflated, and subsequently inserted into the cavity. At least one therapeutic agent may be injected into the first collapsible resorbable hollow device. According to another implementation of the method, a second collapsible resorbable hollow device may be provided, and the second device may be inserted into the first collapsible resorbable hollow device. At least one therapeutic agent then may be injected into the second collapsible resorbable hollow device. Various therapeutic agents may be injected according to typical implementations of the present invention. For example, a therapeutic agent may comprise one or more of a natural organic substance, a synthetic organic substance, an inorganic substance, and combinations thereof.
- Furthermore, the function of the hollow devices can encompass both encapsulation and therapeutic substance delivery roles simultaneously. An embodiment of the present invention may further comprise a collapsible resorbable balloon formed of resorbable material such as, for example, aliphatic polyesters, polycarbonates, polyoxaesters, polyorthoesters, polyanhydrides, polyphosphoesters, polyphosphazenes, polypropylene fumarates, polyamino acids, other polyamides, pseudopoly(amino acids), polyamidoesters, polyarylates, polyoxaesters containing amine groups, polyalkylene oxalate, polyhydroxybuyrate, polyhydroxyvalerate, resorbable polyurethanes, resorbable starches, resorbable silk, chitan or chitosan, and combinations (co- or multi-polymers or blends) of any of the above with or without, for example, nonresorbable polymers and/or natural substances.
- While the apparatus and methods of the present invention have or may be described for the sake of grammatical fluidity with functional explanations, it is to be expressly understood that the claims, unless expressly formulated under 35 U.S.C. 112, are not to be construed as necessarily limited in any way by the construction of “means” or “steps” limitations, but are to be accorded the full scope of the meaning and equivalents of the definition provided by the claims under the judicial doctrine of equivalents, and in the case where the claims are expressly formulated under 35 U.S.C. 112 are to be accorded full statutory equivalents under 35 U.S.C. 112.
- Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one skilled in the art. For purposes of summarizing the present invention, certain aspects, advantages and novel features of the present invention are described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the present invention. Additional advantages and aspects of the present invention will be apparent in the following detailed description and claims that follow.
-
FIG. 1 is a flow diagram describing an implementation of a method of manufacturing a resorbable balloon; -
FIGS. 2 a-2 g are schematic diagrams illustrating results of applying steps of a method of manufacturing a resorbable balloon in accordance with an implementation of the present invention; -
FIG. 3 is a simplified diagram illustrating a cavity in bone that may be filled with cement by employing a resorbable balloon according to the present invention; -
FIG. 4 is a flow diagram describing an implementation of a method of delivering a therapy or therapeutic agent employing collapsible resorbable hollow devices; -
FIG. 5 is a pictorial diagram illustrating three resorbable hollow devices according to an example of the present invention; -
FIG. 6 is a pictorial diagram illustrating the three resorbable hollow devices ofFIG. 5 with openings sealed or closed in some way, if needed, and conduits removed; and -
FIG. 7 is a graphical chart illustrating timed-release delivery of therapeutic agents. - Reference will now be made in detail to the presently preferred embodiments of the invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same or similar reference numbers may be used in the drawings and the description to refer to the same or like parts. It should be noted that the drawings are in simplified form and are not to precise scale. In reference to the disclosure herein, for purposes of convenience and clarity only, directional terms, such as, top, bottom, left, right, up, down, over, above, below, beneath, rear, and front, may be used with respect to the accompanying drawings. Such directional terms should not be construed to limit the scope of the invention in any manner.
- Although the disclosure herein refers to certain illustrated embodiments, it is to be understood that these embodiments are presented by way of example and not by way of limitation. The intent of the following detailed description, although discussing exemplary embodiments, is to be construed to cover all modifications, alternatives, and equivalents of the embodiments as may fall within the spirit and scope of the invention as defined by the appended claims. It is to be understood and appreciated that the process steps and structures described herein do not cover complete process flows for the manufacture of resorbable balloons and methods of administration of time-release therapeutic agents using resorbable balloons. The present invention may be practiced in conjunction with various techniques that may be conventionally used in the art, and only so much of the commonly practiced process steps are included herein as necessary to provide an understanding of the present invention. The present invention has applicability in the field of resorbable balloons or hollow devices in general. For illustrative purposes, however, the following description is presented in the context of a biodegradable (e.g., resorbable, bioresorbable, degradable, absorbable, bioabsorbable, erodible, or bioerodible) balloon for vertebroplasty and kyphoplasty applications and methods of manufacturing a biodegradable balloon, and in the context of biodegradable (e.g., resorbable, bioresorbable, degradable, absorbable, bioabsorbable, erodible, or bioerodible) balloons for delivering therapeutic agents over a distributed time span.
- Referring more particularly to the drawings,
FIG. 1 is a flow diagram describing an implementation of the inventive methods of manufacturing a resorbable (e.g., bioresorbable, degradable, biodegradable, absorbable, bioabsorbable, erodible, bioerodible) balloon. This implementation will be described with reference toFIGS. 2 a-2 g, which illustrate a representative sequence of performing steps of the methods. The illustrated embodiment of the described inventive methods comprises extruding resorbable tubing atstep 10. The tubing extruded may comprise, for example, polymeric tubing in a representative embodiment.FIG. 2 a illustrates an example of amold 50 from which is extrudedtubing 55. In typical embodiments, thetubing 55 may have a circular cross-section with anouter diameter 60 ranging, for example, from about 0.7 mm to about 15 mm and aninner diameter 65 that may range, for example, from about 0.5 mm to about 9 mm. That is, the tubing may exhibit a wall thickness of, for example, about 0.1 mm to about 3 mm in common embodiments. Thetubing 55 may be cut into portions atstep 15, wherein the portions may have various lengths according to varying intended applications. Tubes of resorbable material may thus be formed from the cutting performed atstep 15. For example, a portion of tubing intended for use in angioplasty may range in length from, for example, about 50 mm to about 300 mm. A portion of tubing intended for use in vertebroplasty applications typically may be cut into lengths ranging in length from, for example, about 15 mm to about 100 mm.FIG. 2 b illustrates twosuch tubes - A portion of the tubing, e.g. tube 70 (
FIG. 2 b), then may be heated in a selected region atstep 20. For example, a center region of the tube may be selected and heated.FIG. 2 c illustrates acenter region 85 oftube 70 being heated by an embodiment of an external heat source, which may comprise, for example, a mold formed, for example, of metal. In the illustrated embodiment, the mold comprises aheated mold 90. Theheated mold 90 may comprise an internal chamber orcavity 91 having a shape and size equal or corresponding to, for example, one or more of a final balloon size and a final balloon shape. An exemplary embodiment of theheated mold 90 compriseselectrical coils 92 through which may be passed a current 93 supplied from anelectrical power source 94. Other internal heating means, and/or even external heating means, such as heating elements (e.g., flames) and/or electromagnetic energy (EM) emitting sources used for example with nonmetallic (e.g., non-EM blocking) molds, may be implemented in modified embodiments. - Regardless of the means used for providing heat, the
heated mold 90 may in certain embodiments be configured to provide heat (and/or cooling), for example, in different amounts along one or more of: (a) at least one spatial dimension (e.g., along a longitudinal axis of the heated mold 90), and (b) a time dimension (e.g., at different points in time and/or for different durations). For example, when tubing is inserted into theheated mold 90 such that a longitudinal axis of the tubing is substantially aligned with a longitudinal axis of theheated mold 90, and when as in the illustrated embodiment tubing near the center of thecavity 91 is substantially further from walls of theheated mold 90 than tubing at ends of thecavity 91, greater amounts of heat energy may be provided near the center of thecavity 91 at certain points in time such as during the process ofFIG. 2 e. According to certain implementations, the tubing can be inserted into theheated mold 90 prior to any pre-stretching of the tubing. - Electrical coils in an illustrated embodiment of the
heated mold 90 may be fabricated to have, for example, greater resistance in a center region of theheated mold 90 than at edges. Such an arrangement may provide greater I2R heating of metal near the center of theheated mold 90, wherein I represents current and R represents resistance. Thus, in an illustrative embodiment wherein theheated mold 90 comprises a block of metal housingelectrical coils 92, certain parts of the heated portions ofelectrical coils 92 may be formed to comprise greater resistances (or other heating structures) to thereby provide varying amounts of heat at the heated portions of theelectrical coils 92. - In an exemplary operation, tubing may be fed down a middle of the
heated mold 90, and current 93 then turned on to raise a temperature of theheated mold 90. Typically, theheated mold 90 heats the tubing material to a temperature greater than a glass transition temperature, but below a melting temperature, of a material (e.g., a polymer) forming the tubing. - The
heated center region 85, which is indicated inFIG. 2 c with shading, is bounded by relativelyunheated regions heated center region 85. According to an implementation of the methods of the present invention, after a condition has been met, such as an occurrence of one or more of a predetermined time period and a predetermined temperature, thematerial forming tube 70 may be pulled. In one embodiment, the material forming thetube 70 is pulled while being heated. When polymeric tubing is used, such pulling may accomplish one or more of strengthening and orienting a polymer or polymers of the tubing and causing the tubing wall to thin in the heated region. The pulling may increase the length of the heated center region of thetube 85 in a range of, for example, about 0 percent to about 1000 percent. The thickness of the thinnedtubing wall 95 in theheated center region 85 may range from, for example, about 0.01 mm to about 0.5 mm whenstep 20 is concluded.FIG. 2 d is a pictorial representation of an implementation of the heating/pulling operation just described. The pulling may be implemented, for example, by applyingaxial forces tube 70. - A balloon may be formed in the resorbable tube by forcing heated air through a lumen of the tube at
step 25 while, in the illustrated embodiment, continuing to apply external heat, thereby causing the tubing to expand in the selected region.FIG. 2 e illustrates the process. Fluid, such as air, which in the illustrated embodiment may compriseheated air 110, is directed, e.g., forced, into thetube 70. The directing of the fluid into thetube 70, e.g., into one or more ends of thetube 70, may result in one or more of further thinning of awall 97 of thetube 70 and formation of a balloon 100 (FIG. 2 f). In the illustrated embodiment, the directing of fluid into thetube 70 causes a pressure increase inside thetube 70. As presently embodied, the effect of the heat applied from theheated mold 90 and the heat of theheated air 110 can cause thetube 70 to expand in thecenter region 85, which action may result in thinning of thewall 97 of thetube 70 and formation of aballoon 100. According to certain implementations, fluid in the form of a gas or liquid may be directed through a lumen of thetube 70 prior to stretching of thetube 70. In certain implementations, the mold may provide cooling only while fluid in the form of a gas or liquid is be directed through a lumen of thetube 70 causing expansion of the tube. -
Exhaust air 111 may be directed out of thetube 70 via, for example, an end of thetube 70 that is opposite to an end through which the fluid is directed. According to this method, the thickness of thewall 97 of theballoon 100 may in the illustrated embodiment be reduced to a thickness of, for example, about 0.005 mm to about 0.1 mm.FIG. 2 f illustrates an example of aballoon 100 formed according to the aforementioned steps after theheated mold 90 and a source of forcedheated air 110 have been removed. In certain embodiments, theheated mold 90 may be partially or substantially completely (e.g., below a glass transition temperature) cooled before removal of theballoon 100 from theheated mold 90. Fabrication of theballoon 100 can then be completed by, for example, at least partially modifying, e.g., sealing, an end of the tube near theballoon 100 atstep 30. For example, inFIG. 2 g, aresorbable plug 115 is shown formed, e.g., integrally formed using heat, or affixed, e.g., adhered or glued, to an end of theballoon 100, thereby providing, for example, a seal at an end of the tube that is disposed in close proximity to theballoon 100. Excess tubing, corresponding for example to a relatively unheated region 80 (FIG. 2 f), can be removed, e.g., cut off, beyond the sealed point as depicted in the embodiment ofFIG. 2 g. According to an alternative implementation of the method, one end of the tube can be modified, e.g., heat crimped, plugged, or otherwise closed, before theballoon 100 is formed, i.e., before the performance ofstep 20. Once formed, theballoon 100 may, for example, be deflated and configured, e.g., folded or twisted, to a cross-section of, for example, about the size of the relativelyunheated region 81. -
FIG. 3 is a simplified diagram illustrating a cavity in bone that may be filled with cement by employing a resorbable balloon in accordance with an aspect of the present invention. Bone such as vertebral bodies of the spine in a patient is represented inFIG. 3 by twocylinders cushioning disk 155. Arepresentation 160 of a spinal cord that passes through thevertebrae disk 155 also is shown. Acavity 165 has been formed invertebra 151 representing a cavity that may be formed in, for example, an injured or osteoporotic spine. Anaccess passageway 170 formed in thevertebra 151 provides a means for access to thecavity 165. In at least one implementation, a diameter, e.g., a maximum diameter, of theaccess passageway 170 is less than a diameter, e.g., a maximum diameter, of thecavity 165. In other embodiments, however, a diameter of theaccess passageway 170 may be about equal to or greater than a corresponding, e.g., measured in the same or similar direction, diameter of thecavity 165. - In accordance with an aspect of the present invention, tubing comprising a resorbable balloon that is similar to the
balloon 100 illustrated inFIG. 2 g can be formed as described herein. A property, e.g., dimension such as diameter, of the tubing is chosen such that the tubing and the balloon in its deflated state are capable of being inserted throughaccess passageway 170 and into thecavity 165. For instance, properties of the tubing and/or balloon may be selected such that the tubing and balloon may be folded to facilitate insertion through theaccess passageway 170. According to at least one implementation, the tubing and balloon are maneuvered through theaccess passageway 170 and into thecavity 165 using a catheter. Once inside thecavity 170, a material such as bone cement may be inserted, e.g., injected, into a lumen of the tube. In implementations comprising a catheter, the material may be delivered directly into the balloon via the catheter, wherein, for example, the material does not contact internal surfaces of the tubing during transit to the balloon. Other implementations may comprise, for example, delivery of the material into the balloon via the tubing itself, wherein, for example, the material contacts the tubing during transit to the balloon. In one embodiment, insertion of the material at least partially fills, e.g., inflates, the balloon. - According to an illustrated embodiment, one or more of a size and a shape of the balloon can be chosen such that the balloon is capable of conforming to sides of the
cavity 165 when, for example, the balloon is inflated. In implementations utilizing a catheter, once the material has been delivered into the balloon and, for example, the balloon has expanded to substantially fill thecavity 165, the catheter may be removed from the resorbable balloon, whereby the balloon with the material remains inside the cavity. Thus, a resorbable balloon can be positioned within a cavity and filled with a material to accomplish expansion and conformance of the balloon to interior dimensions of the cavity. - As presently embodied, with a passage of time at least a part of the balloon degrades, causing the material within the balloon to be delivered into contact with a corresponding interior surface or surfaces of or within the cavity. In particular implementations, the resorbable balloon is not removed and resorbs substantially completely within the cavity. Resorption of the balloon can be engineered to occur, for example, after the material has contacted and at least partially reacted, e.g., bonded, with interior surfaces within the cavity. In exemplary embodiments comprising a cavity formed in bone, material comprising bone cement can be positioned within a resorbable, expandable balloon, combined, in some implementations, with one or more of an antiobiotic, analgesic, growth factor (such as Bone Morphogenetic Protein), or a combination thereof, to contact interior surfaces of a cavity formed within bone, thereby permitting one or more of reacting, hardening, and bonding to occur between the material and the bone upon resorption of the balloon. Consequently, risks of one or more of infection and pain can be attenuated or eliminated.
-
FIG. 4 is a flow diagram describing an implementation of a method of performing therapy employing collapsible resorbable hollow devices. According to the implementation described in the figure, a collapsible, resorbable hollow device, cavity, or balloon is provided atstep 110. A method of fabricating collapsible, resorbable hollow devices of a type appropriate to the implementation is described in U.S. Provisional Application No. 60/653,778, the entire contents of which are hereby incorporated by reference. Althoughstep 110 of the implementation comprises providing a single collapsible, resorbable hollow device, other implementations may comprise providing two or more collapsible, resorbable hollow devices. - In other implementations, the collapsible, resorbable hollow devices may be nested as illustrated, for example, in
FIG. 5 . The collapsible, resorbable hollow devices may be designed to deliver or release at least one therapeutic agent. As part of the fabrication of the hollow device, a conduit or tube may be attached, if needed (e.g., suitable or desired), to an opening of the device atstep 120 of the implementation. According to another embodiment, the conduit may be formed as a continuous part of the hollow device. The conduit (see, e.g.,FIG. 5 ) may facilitate loading of the hollow device with at least one therapeutic agent. Additionally, the conduit may aid in positional manipulation of the hollow device. - A surgical procedure, which may be a laparoscopic procedure, may be performed, if needed (e.g., suitable or desired), at
step 130 to identify a cavity in an anatomical location. As presently embodied, a cavity in a desired anatomical location may also be formed. For example, a cavity may be formed in soft tissue using a tissue expander. Alternatively, a cavity may be formed in a collapsed vertebra of the spine of a patient, wherein therapy is to be performed. As another example, a cavity may be identified in the abdomen or other part of the body of a patient near an abscess requiring antibiotic therapy. Once the cavity is formed or identified, the hollow device may, to the extent inflated, be at least partially deflated atstep 140, and the hollow device inserted into the cavity atstep 150. The attached conduit, for example, may facilitate insertion and positional manipulation of the hollow device. A therapeutic agent, such as an antibiotic, may be injected into the hollow device atstep 160, thereby inflating the hollow device. Alternatively, the hollow device may be inflated before the therapeutic agent is injected. According to other implementations, the inflating may be performed by altering an internal or external physical or chemical environment of the device when the device is in living tissue. The conduit may also be used to transfer the therapeutic agent into the hollow device. The opening may be closed atstep 170 after which the conduit may then be removed, if needed (e.g., suitable or desired), from the hollow device atstep 180. According to another implementation, the opening is closed after removal of the conduit. In yet another implementation, the opening is closed during removal of the conduit. In yet another implementation, the opening is not closed, as may occur when the device is used to transfer gelling or polymerizing substances as therapeutic agents. - The therapeutic agent may be delivered in a time-released manner according to specific properties of the hollow device. For example, the device may be fabricated with varying thicknesses or with relatively small perforations or holes, sizes of which may be adjusted to achieve a desired rate of delivery of the therapeutic agent. In other examples, more than one collapsible, resorbable hollow device may be employed. A second collapsible device may be inserted inside a first collapsible hollow device, the first device then being injected with one or more or a combination of therapeutic agents. The second collapsible device then may be inflated, and yet another therapeutic agent or combination thereof may be injected into the second device. This process may be continued by nesting a plurality of collapsible, resorbable hollow devices in a manner that should be clear to one skilled in the art from the disclosure provided herein. When a plurality of hollow devices or balloons is employed, openings of the hollow devices may be closed separately before, after, or during removal of conduits associated with each device. In some instances, the openings may be closed together. In still other examples, nested hollow devices may be made with differing materials or geometry (shapes). Alternatively, space, or lack of space, between the devices can be used to achieve desired patterns of release of therapeutic material.
-
FIG. 5 is a pictorial diagram illustrating an embodiment comprising a plurality of nested hollow devices according to the present invention. Although only three such devices are illustrated in the figure, one skilled in the art will understand that more or fewer hollow devices may be employed so that a description of three devices is by way of example and not by way of limitation. In the illustrated embodiment, a first collapsible, resorbablehollow device 200 is inflated and fully or partially filled with a firsttherapeutic agent 205. That is, the first collapsible, resorbablehollow device 200 may, in some instances, be partially filled in order to leave room for insertion of subsequent hollow devices. As already noted, the first therapeutic agent, as well as below-referenced additional therapeutic agents, may comprise one or more or a combination of individual therapeutic agents. The firsttherapeutic agent 205 may be loaded into the firsthollow device 200 through a first tube orfirst conduit 210 formed as part of the first hollow device. Loading of firsttherapeutic agent 205 is noted on the diagram byreference numeral 215. A second collapsible, resorbablehollow device 220 may be inserted usingsecond conduit 230 in deflated form, and thedevice 220 then may be partially or fully inflated. According to an exemplary embodiment, loading the secondhollow device 220 with a secondtherapeutic material 225 throughsecond conduit 230 as denoted byreference numeral 235 may serve to inflate the secondhollow device 220, thereby displacing or redistributing a portion of the firsttherapeutic agent 205 already loaded. Continuing, a third collapsible, resorbablehollow device 240 may likewise be inserted into thesecond device 220 and loaded usingthird conduit 250 as indicated byreference numeral 255. Once in place, respective first, second, andthird conduits seal 260 in place as illustrated inFIG. 6 . - The collapsible, resorbable
hollow devices FIGS. 5 and 6 may be formed of various materials. For example, a representative hollow device can be made with a resorbable synthetic polymer including by way of example, and not by way of limitation, one or more of aliphatic polyesters (e.g., polyL-lactide, polyD-lactide, polyglycolide, poly epsilon-caprolactone, and the like), polycarbonates (e.g., polytrimethylene carbonate, tyrosine derived polycarbonates, and polyiminocarbonates), polyoxaesters (e.g., polyp-dioxanone), polyorthoesters, polyanhydrides, polyphosphoesters, polyphosphazenes, polypropylene fumarates, polyamides (e.g., polyaminoacids), pseudopoly(amino acids), polyamidoesters, polyarylates, polyoxaesters containing amine groups, polyalkylene oxalate, polyhydroxybuyrate, polyhydroxyvalerate, resorbable polyurethanes, resorbable starches, resorbable silk, chitan or chitosan and combinations (co- or multi-polymers or blends) of any of the above with or without, for example, nonresorbable polymers (e.g., polyethylene oxide, and polyvinyl alcohol) and/or natural substances, and other combinations thereof. Depending at least in part upon fabrication material, hollow devices may be made to resorb (e.g., bioresorb, degrade, biodegrade, absorb, bioabsorb, erode, or bioerode) over time periods ranging from a few days to a number of years according to a desired release rate of a therapeutic agent. - Therapeutic agents may have the consistency of, for example, one or more of a liquid, gel, powder, small granules, spheres or chips, a polymerizable substance, and combinations thereof, and likewise, may be chosen from a variety of possibilities. For example, a natural organic substance can be or include one or more of living biological agents (e.g., cells), proteins (e.g., growth factors such as Bone Morphogenetic Protein, and the like), other natural polymers (e.g., collagen, gelatin, fibrin, hyaluronic acid, polysaccharides, elastin, cellulose, polynucleotides), other biological materials, and the like. Combinations of these and similar materials also may be used. In other instances, the therapeutic agent may comprise a synthetic organic substance, such as, for example, one or more of a drug, antibiotic, steroid, glycerol, polymer (e.g., polyester, silicone, polyethylene oxide, polypropylene fumarate, pluronics, polyhydroxymethacrylate, or polymethylmethacrylate), and the like, and combinations thereof. In still other cases, the therapeutic agent may comprise an inorganic substance, such as, for example, one or more of calcium phosphate (e.g., beta-tricalcium phosphate or hydroxapatite), allograft bone, other ceramics or metals, and combinations thereof. The therapeutic agents may be made in combinations from any of the above components or groups or other suitable carrier(s), examples of which may include cells loaded in a pluronic gel or growth factors and antibiotics mixed with an inorganic substance.
-
FIG. 7 is a chart illustrating in graphical form an example of how release of a therapeutic agent may be controlled through use of resorbable hollow devices in a repeat action dosage form. The chart illustrates a variation of local concentration or amount of a therapeutic agent on avertical axis 300 during a time period drawn on ahorizontal axis 305. The amount of therapeutic agent to be released normally is to be kept between a minimumtherapeutic level 310 and a maximumtherapeutic level 315. The maximumtherapeutic level 315 may correspond as well to a toxicity level. The chart ofFIG. 7 is keyed to the first, second, and third resorbablehollow devices FIGS. 5 and 6 . In the example illustrated, firsthollow device 200 becomes resorbed (i.e. degrades) at afirst time 320 releasing afirst wave 325 of the therapeutic agent. As time increases to the right, the level of therapeutic agent represented byfirst wave 325 decreases. At asecond time 330, secondhollow device 220 degrades releasing asecond wave 335 of the therapeutic agent. Similarly, thirdhollow device 240 degrades at athird time 340 releasing athird wave 345 of the therapeutic agent. The actual elapsed time between degradation of the first, second, and thirdhollow devices times therapeutic agents FIGS. 5 and 6 ), likewise, may be the same or different in different embodiments of the present invention. - For example, first, second, and third resorbable
hollow devices therapeutic agents therapeutic agents therapeutic agents hollow devices minimum level 310 and below the maximum therapeutic level or below thetoxicity level 315. In yet another embodiment, a hollow device, such as secondhollow device 220, can be made to have perforations or holes, or no perforations, and may be covered or layered with another hollow device, such as firsthollow device 200 having a faster degradation rate. This arrangement may allow release of the secondtherapeutic agent 225 through the holes of the second hollow device 220 (i.e., the more slowly degrading device) when the first hollow device 200 (i.e., the more rapidly degrading device) degrades. - In view of the foregoing, it will be understood by those skilled in the art that the methods of the present invention can facilitate formation of resorbable balloons and control of time-release therapeutic agents using collapsible, resorbable hollow devices or balloons. The above-described embodiments have been provided by way of example, and the present invention is not limited to the described examples. Multiple variations and modifications to the disclosed embodiments will occur, to the extent not mutually exclusive, to those skilled in the art upon consideration of the foregoing description. For example, the resorbable balloon may be used for other implanting applications such as a bariatric balloon, breast augmentation balloon, etc. Furthermore, modifications to the above-described manufacturing techniques may include, for example, a continuous extrusion and balloon forming method, and alternative implementations of such techniques may include, for example, extrusion of tubing with one closed end resembling the shape of, for example, a blow molding parison. Other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the disclosed embodiments, but is to be defined by reference to the appended claims.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/624,217 US20100065989A1 (en) | 2005-02-16 | 2009-11-23 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65377805P | 2005-02-16 | 2005-02-16 | |
US67283905P | 2005-04-18 | 2005-04-18 | |
US11/357,837 US20060182780A1 (en) | 2005-02-16 | 2006-02-16 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
US12/624,217 US20100065989A1 (en) | 2005-02-16 | 2009-11-23 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/357,837 Continuation US20060182780A1 (en) | 2005-02-16 | 2006-02-16 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100065989A1 true US20100065989A1 (en) | 2010-03-18 |
Family
ID=37115617
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/357,837 Abandoned US20060182780A1 (en) | 2005-02-16 | 2006-02-16 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
US12/424,140 Active 2029-12-25 US9662152B2 (en) | 2005-02-16 | 2009-04-15 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
US12/624,217 Abandoned US20100065989A1 (en) | 2005-02-16 | 2009-11-23 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/357,837 Abandoned US20060182780A1 (en) | 2005-02-16 | 2006-02-16 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
US12/424,140 Active 2029-12-25 US9662152B2 (en) | 2005-02-16 | 2009-04-15 | Resorbable hollow devices for implantation and delivery of therapeutic agents |
Country Status (4)
Country | Link |
---|---|
US (3) | US20060182780A1 (en) |
EP (1) | EP1848489A2 (en) |
CN (1) | CN101370634A (en) |
WO (1) | WO2006112941A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110034885A1 (en) * | 2009-08-05 | 2011-02-10 | The University Of Toledo | Needle for directional control of the injection of bone cement into a vertebral compression fracture |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2594492A1 (en) | 1999-03-07 | 2000-09-14 | Active Implants Corporation | Method and apparatus for computerized surgery |
AU2005257050A1 (en) | 2004-06-23 | 2006-01-05 | Bioprotect Ltd. | Device system and method for tissue displacement or separation |
US7722620B2 (en) | 2004-12-06 | 2010-05-25 | Dfine, Inc. | Bone treatment systems and methods |
US9066769B2 (en) | 2005-08-22 | 2015-06-30 | Dfine, Inc. | Bone treatment systems and methods |
US20070162043A1 (en) * | 2005-09-01 | 2007-07-12 | Csaba Truckai | Methods for sensing retrograde flows of bone fill material |
CA2680812C (en) | 2007-03-15 | 2017-01-24 | Ortho-Space Ltd. | Prosthetic devices and methods for using same |
CN101686855A (en) * | 2007-03-15 | 2010-03-31 | 生物保护有限公司 | Soft tissue fixation devices |
US8523871B2 (en) | 2007-04-03 | 2013-09-03 | Dfine, Inc. | Bone treatment systems and methods |
US8480647B2 (en) * | 2007-05-14 | 2013-07-09 | Bioprotect Ltd. | Delivery device for delivering bioactive agents to internal tissue in a body |
US20090061002A1 (en) * | 2007-09-05 | 2009-03-05 | Venbrocks Rudolf A | Calcium phospate based delivery of growth and differentiation factors to compromised bone |
WO2009053820A1 (en) * | 2007-10-24 | 2009-04-30 | Sbf Synthetic Bone Factory Gmbh | System for treating bone and/or cartilage defects and methods of use therefor |
JP5366966B2 (en) * | 2007-11-16 | 2013-12-11 | ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Porous containment device and related method for stabilizing vertebral compression fractures |
WO2010100287A1 (en) | 2009-03-06 | 2010-09-10 | Somatex Medical Technologies Gmbh | Barrier for implantation into bone, in particular for vertebroplasty |
DE102009011561A1 (en) | 2009-03-06 | 2010-09-16 | Somatex Medical Technologies Gmbh | Barrier for implantation into bone in vertebroplasty use in injection apparatus, has closure apparatus placed on or in filling hole to automatically close or clog hole after completion of filling of bag |
US8911497B2 (en) * | 2009-04-09 | 2014-12-16 | DePuy Synthes Products, LLC | Minimally invasive spine augmentation and stabilization system and method |
WO2011083474A2 (en) | 2010-01-07 | 2011-07-14 | Bioprotect Ltd. | Controlled tissue dissection systems and methods |
US9220554B2 (en) | 2010-02-18 | 2015-12-29 | Globus Medical, Inc. | Methods and apparatus for treating vertebral fractures |
US8945224B2 (en) * | 2010-03-18 | 2015-02-03 | Warsaw, Orthopedic, Inc. | Sacro-iliac implant system, method and apparatus |
US20130116794A1 (en) | 2010-08-04 | 2013-05-09 | Shaul Shohat | Shoulder implant |
WO2013057566A2 (en) | 2011-10-18 | 2013-04-25 | Ortho-Space Ltd. | Prosthetic devices and methods for using same |
CN102525609B (en) * | 2012-03-09 | 2013-06-12 | 上海凯利泰医疗科技股份有限公司 | Double-sacculus catheter structure |
WO2014098880A1 (en) * | 2012-12-20 | 2014-06-26 | Empire Technology Development, Llc | Inflatable balloon for protecting blood vessel |
US8734459B1 (en) | 2013-01-17 | 2014-05-27 | Abdulrazzaq Alobaid | Device and method to prevent extravasation of bone cement used in balloon kyphoplasty |
US9580678B2 (en) | 2013-06-21 | 2017-02-28 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device |
US9539041B2 (en) | 2013-09-12 | 2017-01-10 | DePuy Synthes Products, Inc. | Minimally invasive biomaterial injection system |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
BR112018075194B1 (en) | 2016-06-08 | 2023-01-10 | The Regents Of The University Of California | METHOD AND DEVICE TO PROCESS SAMPLES |
DE102016111886A1 (en) * | 2016-06-29 | 2018-01-04 | Silony Medical International AG | Expandable intervertebral implant |
CN110141760B (en) * | 2019-06-05 | 2021-10-08 | 山东百多安医疗器械股份有限公司 | Centrum forming expansion balloon with drug loaded on surface and preparation method thereof |
EP4178496A4 (en) * | 2020-07-08 | 2024-08-14 | 4Web Inc | Implants having bone growth promoting agents contained within biodegradable materials |
CN112168325A (en) * | 2020-09-27 | 2021-01-05 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Balloon for vertebroplasty and medical device |
WO2022112057A1 (en) * | 2020-11-27 | 2022-06-02 | Bw-Tec Ag | Balloon forming process |
US11771562B2 (en) * | 2021-01-28 | 2023-10-03 | The Second Affiliated Hospital And Yuying Children's Hospital Of Wenzhou Medical University | Balloon, medical device and medical procedure for discoplasty |
CN112844873A (en) * | 2021-02-03 | 2021-05-28 | 陕西中医药大学 | A splitter for traditional chinese medicine solid-liquid separation |
US11298238B1 (en) * | 2021-07-23 | 2022-04-12 | Focus Medical Company, Llc | Balloon kyphoplasty surgical device and method |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173418A (en) * | 1961-01-10 | 1965-03-16 | Ostap E Baran | Double-wall endotracheal cuff |
US3297033A (en) * | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
US3901232A (en) * | 1973-10-26 | 1975-08-26 | Alza Corp | Integrated device for administering beneficial drug at programmed rate |
US3944064A (en) * | 1973-10-26 | 1976-03-16 | Alza Corporation | Self-monitored device for releasing agent at functional rate |
US3981299A (en) * | 1971-03-15 | 1976-09-21 | Harry Elmer Murray | Urethral catheter |
US3993073A (en) * | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3993072A (en) * | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4147767A (en) * | 1975-10-09 | 1979-04-03 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
US4254774A (en) * | 1979-02-14 | 1981-03-10 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Balloon catheter and technique for the manufacture thereof |
US4305392A (en) * | 1978-09-29 | 1981-12-15 | Chester Martin H | Endotracheal tube with suction device |
US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
US4417576A (en) * | 1982-02-25 | 1983-11-29 | Baran Ostap E | Double-wall surgical cuff |
US4518383A (en) * | 1982-08-06 | 1985-05-21 | Evans John M | Instrument and method for epidural and spinal anaesthesia |
US4693243A (en) * | 1983-01-14 | 1987-09-15 | Buras Sharon Y | Conduit system for directly administering topical anaesthesia to blocked laryngeal-tracheal areas |
US4906244A (en) * | 1988-10-04 | 1990-03-06 | Cordis Corporation | Balloons for medical devices and fabrication thereof |
US4925677A (en) * | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US4938763A (en) * | 1988-10-03 | 1990-07-03 | Dunn Richard L | Biodegradable in-situ forming implants and methods of producing the same |
US4983392A (en) * | 1983-11-14 | 1991-01-08 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
US4994033A (en) * | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US5041090A (en) * | 1988-01-12 | 1991-08-20 | Scheglov Viktor I | Occluding device |
US5045071A (en) * | 1985-12-17 | 1991-09-03 | Mbo Laboratories, Inc. | Double wall catheter with internal printing and embedded marker |
US5084315A (en) * | 1990-02-01 | 1992-01-28 | Becton, Dickinson And Company | Lubricious coatings, medical articles containing same and method for their preparation |
US5207071A (en) * | 1991-04-26 | 1993-05-04 | Kabushiki Kaisha Toshiba | Current control apparatus for air-conditioning system |
US5209741A (en) * | 1991-07-08 | 1993-05-11 | Endomedix Corporation | Surgical access device having variable post-insertion cross-sectional geometry |
US5254091A (en) * | 1991-01-08 | 1993-10-19 | Applied Medical Resources Corporation | Low profile balloon catheter and method for making same |
US5318531A (en) * | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
US5618286A (en) * | 1992-08-20 | 1997-04-08 | Brinker; Mark | Antibiotic eluding intramedullary nail apparatus |
US5780044A (en) * | 1994-04-08 | 1998-07-14 | Atrix Laboratories, Inc. | Liquid delivery compositions |
US5800421A (en) * | 1996-06-12 | 1998-09-01 | Lemelson; Jerome H. | Medical devices using electrosensitive gels |
US5868705A (en) * | 1996-05-20 | 1999-02-09 | Percusurge Inc | Pre-stretched catheter balloon |
US5888533A (en) * | 1995-10-27 | 1999-03-30 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5904934A (en) * | 1993-06-23 | 1999-05-18 | Alza Corporation | Ruminal drug delivery device |
US5910133A (en) * | 1993-04-13 | 1999-06-08 | Gould; Derek Alan | Transintimal recanalisation device |
US5968047A (en) * | 1996-04-05 | 1999-10-19 | Reed; Thomas Mills | Fixation devices |
US6544221B1 (en) * | 2000-08-30 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon designs for drug delivery |
US20030139811A1 (en) * | 2000-11-03 | 2003-07-24 | Control Delivery Systems, Inc. | Device and Method for Treating Conditions of a Joint |
US6599462B1 (en) * | 1997-06-11 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Balloon catheter having non-bonded integral balloon and methods for its manufacture |
US6645422B2 (en) * | 1997-05-14 | 2003-11-11 | Jomed, Inc. | Method for manufacturing a balloon for a dilation catheter |
US6656488B2 (en) * | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
US6716216B1 (en) * | 1998-08-14 | 2004-04-06 | Kyphon Inc. | Systems and methods for treating vertebral bodies |
US20050021084A1 (en) * | 2003-05-19 | 2005-01-27 | Lu William Weijia | Bone treatment device and method |
US20050146085A1 (en) * | 2004-01-07 | 2005-07-07 | Scimed Life Systems, Inc. | Process and apparatus for forming medical device balloons |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5685716A (en) * | 1994-10-21 | 1997-11-11 | Linkow; Leonard I. | Apparatus and method for closing a sinus opening during a dental implant operation |
US7618451B2 (en) * | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
US20060271061A1 (en) * | 2001-07-25 | 2006-11-30 | Disc-O-Tech, Ltd. | Deformable tools and implants |
US6852095B1 (en) * | 1997-07-09 | 2005-02-08 | Charles D. Ray | Interbody device and method for treatment of osteoporotic vertebral collapse |
JP4393706B2 (en) * | 1998-06-01 | 2010-01-06 | カイフォン・ソシエテ・ア・レスポンサビリテ・リミテ | Deployable preformed structure for placement within an internal body region |
US6206930B1 (en) * | 1998-08-10 | 2001-03-27 | Charlotte-Mecklenburg Hospital Authority | Absorbable tissue expander |
ES2262642T3 (en) * | 2000-04-05 | 2006-12-01 | Kyphon Inc. | DEVICE FOR THE TREATMENT OF FRACTURED AND / OR SICK BONES. |
DE60141653D1 (en) * | 2000-07-21 | 2010-05-06 | Spineology Group Llc | A STRONG, POROUS NET BAG DEVICE AND ITS USE IN BONE SURGERY |
US6632235B2 (en) * | 2001-04-19 | 2003-10-14 | Synthes (U.S.A.) | Inflatable device and method for reducing fractures in bone and in treating the spine |
US20050209629A1 (en) * | 2001-04-19 | 2005-09-22 | Kerr Sean H | Resorbable containment device and process for making and using same |
AU2003279506A1 (en) * | 2002-11-12 | 2004-06-03 | Regenex Ltd. | Expandable devices and methods for tissue expansion, regenerationand fixation |
EP1594423B1 (en) * | 2003-02-14 | 2009-01-07 | DePuy Spine, Inc. | In-situ formed intervertebral fusion device |
US20040220672A1 (en) * | 2003-05-03 | 2004-11-04 | Shadduck John H. | Orthopedic implants, methods of use and methods of fabrication |
US7608062B2 (en) * | 2003-07-15 | 2009-10-27 | Spinal Generations, Llc | Method and device for delivering medicine to bone |
DE102004016397A1 (en) * | 2004-03-26 | 2005-10-13 | Ossacur Ag | Application aid for the treatment of bone defects |
US7465318B2 (en) * | 2004-04-15 | 2008-12-16 | Soteira, Inc. | Cement-directing orthopedic implants |
US8142462B2 (en) * | 2004-05-28 | 2012-03-27 | Cavitech, Llc | Instruments and methods for reducing and stabilizing bone fractures |
US7628800B2 (en) * | 2005-06-03 | 2009-12-08 | Warsaw Orthopedic, Inc. | Formed in place corpectomy device |
US20070093899A1 (en) * | 2005-09-28 | 2007-04-26 | Christof Dutoit | Apparatus and methods for treating bone |
-
2006
- 2006-02-16 EP EP06735691A patent/EP1848489A2/en not_active Withdrawn
- 2006-02-16 US US11/357,837 patent/US20060182780A1/en not_active Abandoned
- 2006-02-16 WO PCT/US2006/006129 patent/WO2006112941A2/en active Application Filing
- 2006-02-16 CN CNA2006800051952A patent/CN101370634A/en active Pending
-
2009
- 2009-04-15 US US12/424,140 patent/US9662152B2/en active Active
- 2009-11-23 US US12/624,217 patent/US20100065989A1/en not_active Abandoned
Patent Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173418A (en) * | 1961-01-10 | 1965-03-16 | Ostap E Baran | Double-wall endotracheal cuff |
US3297033A (en) * | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
US3993073A (en) * | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3981299A (en) * | 1971-03-15 | 1976-09-21 | Harry Elmer Murray | Urethral catheter |
US3901232A (en) * | 1973-10-26 | 1975-08-26 | Alza Corp | Integrated device for administering beneficial drug at programmed rate |
US3944064A (en) * | 1973-10-26 | 1976-03-16 | Alza Corporation | Self-monitored device for releasing agent at functional rate |
US3993072A (en) * | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4147767A (en) * | 1975-10-09 | 1979-04-03 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
US4305392A (en) * | 1978-09-29 | 1981-12-15 | Chester Martin H | Endotracheal tube with suction device |
US4254774A (en) * | 1979-02-14 | 1981-03-10 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Balloon catheter and technique for the manufacture thereof |
US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
US4417576A (en) * | 1982-02-25 | 1983-11-29 | Baran Ostap E | Double-wall surgical cuff |
US4518383A (en) * | 1982-08-06 | 1985-05-21 | Evans John M | Instrument and method for epidural and spinal anaesthesia |
US4693243A (en) * | 1983-01-14 | 1987-09-15 | Buras Sharon Y | Conduit system for directly administering topical anaesthesia to blocked laryngeal-tracheal areas |
US4983392A (en) * | 1983-11-14 | 1991-01-08 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
US5045071A (en) * | 1985-12-17 | 1991-09-03 | Mbo Laboratories, Inc. | Double wall catheter with internal printing and embedded marker |
US5041090A (en) * | 1988-01-12 | 1991-08-20 | Scheglov Viktor I | Occluding device |
US4925677A (en) * | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US4938763A (en) * | 1988-10-03 | 1990-07-03 | Dunn Richard L | Biodegradable in-situ forming implants and methods of producing the same |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4906244A (en) * | 1988-10-04 | 1990-03-06 | Cordis Corporation | Balloons for medical devices and fabrication thereof |
US4994033A (en) * | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US5084315A (en) * | 1990-02-01 | 1992-01-28 | Becton, Dickinson And Company | Lubricious coatings, medical articles containing same and method for their preparation |
US5254091A (en) * | 1991-01-08 | 1993-10-19 | Applied Medical Resources Corporation | Low profile balloon catheter and method for making same |
US5207071A (en) * | 1991-04-26 | 1993-05-04 | Kabushiki Kaisha Toshiba | Current control apparatus for air-conditioning system |
US5318531A (en) * | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
US5209741A (en) * | 1991-07-08 | 1993-05-11 | Endomedix Corporation | Surgical access device having variable post-insertion cross-sectional geometry |
US5618286A (en) * | 1992-08-20 | 1997-04-08 | Brinker; Mark | Antibiotic eluding intramedullary nail apparatus |
US5910133A (en) * | 1993-04-13 | 1999-06-08 | Gould; Derek Alan | Transintimal recanalisation device |
US5904934A (en) * | 1993-06-23 | 1999-05-18 | Alza Corporation | Ruminal drug delivery device |
US5780044A (en) * | 1994-04-08 | 1998-07-14 | Atrix Laboratories, Inc. | Liquid delivery compositions |
US5888533A (en) * | 1995-10-27 | 1999-03-30 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5968047A (en) * | 1996-04-05 | 1999-10-19 | Reed; Thomas Mills | Fixation devices |
US5868705A (en) * | 1996-05-20 | 1999-02-09 | Percusurge Inc | Pre-stretched catheter balloon |
US5800421A (en) * | 1996-06-12 | 1998-09-01 | Lemelson; Jerome H. | Medical devices using electrosensitive gels |
US6645422B2 (en) * | 1997-05-14 | 2003-11-11 | Jomed, Inc. | Method for manufacturing a balloon for a dilation catheter |
US6599462B1 (en) * | 1997-06-11 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Balloon catheter having non-bonded integral balloon and methods for its manufacture |
US6716216B1 (en) * | 1998-08-14 | 2004-04-06 | Kyphon Inc. | Systems and methods for treating vertebral bodies |
US6544221B1 (en) * | 2000-08-30 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon designs for drug delivery |
US20030139811A1 (en) * | 2000-11-03 | 2003-07-24 | Control Delivery Systems, Inc. | Device and Method for Treating Conditions of a Joint |
US6656488B2 (en) * | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
US20050021084A1 (en) * | 2003-05-19 | 2005-01-27 | Lu William Weijia | Bone treatment device and method |
US20050146085A1 (en) * | 2004-01-07 | 2005-07-07 | Scimed Life Systems, Inc. | Process and apparatus for forming medical device balloons |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110034885A1 (en) * | 2009-08-05 | 2011-02-10 | The University Of Toledo | Needle for directional control of the injection of bone cement into a vertebral compression fracture |
US8377013B2 (en) | 2009-08-05 | 2013-02-19 | The University Of Toledo | Needle for directional control of the injection of bone cement into a vertebral compression fracture |
Also Published As
Publication number | Publication date |
---|---|
US20090259177A1 (en) | 2009-10-15 |
WO2006112941B1 (en) | 2008-12-11 |
US9662152B2 (en) | 2017-05-30 |
CN101370634A (en) | 2009-02-18 |
WO2006112941A2 (en) | 2006-10-26 |
US20060182780A1 (en) | 2006-08-17 |
WO2006112941A3 (en) | 2008-10-16 |
EP1848489A2 (en) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9662152B2 (en) | Resorbable hollow devices for implantation and delivery of therapeutic agents | |
JP6152170B2 (en) | Prosthetic system for the treatment of sinusitis or allergic rhinitis | |
CN109152650B (en) | Minimally invasive methods and systems for hemostasis in a bleeding closed tissue volume | |
AU2010241740B9 (en) | Devices and methods for treating pain associated with tonsillectomies | |
US7048714B2 (en) | Drug eluting medical device with an expandable portion for drug release | |
JP2836878B2 (en) | Intraluminal sealing with biodegradable polymer material | |
US6682555B2 (en) | Methods for treating the prostate and inhibiting obstruction of the prostatic urethra using biodegradable stents | |
KR101737335B1 (en) | Expandable implant | |
AU2006231506B2 (en) | Device and methods for treating paranasal sinus conditions | |
US20040230316A1 (en) | Method for treating the prostate and inhibiting obstruction of the prostatic urethra using biodegradable stents | |
US5653760A (en) | Method and apparatus for managing macromolecular distribution | |
US20100076484A1 (en) | Method and apparatus for repairing vascular abnormalities and/or other body lumen abnormalities using an endoluminal approach and a flowable forming material | |
CA2483580A1 (en) | Biodegradable polymer for marking tissue and sealing tracts | |
CN102573981A (en) | Expandable devices and methods therefor | |
JPH11313895A (en) | Bellows medical structure and device using the same | |
CA2782044C (en) | Adhesive delivery devices, systems and methods | |
US20120130489A1 (en) | Methods and apparatus for in situ formation of surgical implants | |
JP2024514509A (en) | Compressible Support Having Drug Dosage Control Features - Patent application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VACCARO, ALEXANDER R.,PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RILEY, SUSAN LYNN;TAI, JOSEPH;REEL/FRAME:023559/0775 Effective date: 20060331 |
|
AS | Assignment |
Owner name: NUVASIVE, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VACCARO, ALEXANDER R.;REEL/FRAME:027729/0058 Effective date: 20111011 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NORTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNORS:NUVASIVE, INC.;NUVASIVE CLINICAL SERVICES MONITORING, INC.;NUVASIVE CLINICAL SERVICES, INC.;AND OTHERS;REEL/FRAME:052918/0595 Effective date: 20200224 |